Robotic Cardiac Surgery: Overview of All Robotic Platforms in Clinical Use Authors: Danny Ramzy, Stephen Waterford Published: 2026 ABSTRACT AbstractRobot-assisted surgery has emerged as a transformative advancement in modern operative care, enabling enhanced visualization, dexterity, and precision. Although adoption has been rapid across multiple surgical specialties, integration into cardiac surgery has evolved more gradually due to the technical complexity of procedures and the requirement for consistently excellent outcomes. Robotic mitral valve repair represents the most mature application of robotic cardiac surgery, demonstrating excellent perioperative outcomes and long-term durability. Emerging robotic platforms are expanding the competitive landscape, while innovations in telerobotics and teleproctoring are poised to improve access and scalability. Robotic cardiac surgery is transitioning toward broader integration. Continued technological innovation, cost reduction, and global dissemination of expertise will define the next phase of its evolution.Keywords: robotic platforms, robotic cardiac surgery Central Message The future of cardiac surgery will be shaped by technological advancements and the ability to integrate these innovations into clinical practice to improve patient outcomes and expand access to high-quality care. Introduction Robot-assisted surgery represents a paradigm shift in operative medicine, enabling surgeons to overcome fundamental limitations of conventional minimally invasive techniques. Traditional laparoscopy and thoracoscopy are constrained by rigid instrumentation with limited degrees of freedom and reliance on 2-dimensional imaging. Robotic systems address these challenges by providing articulated instruments, tremor filtration, motion scaling, and immersive 3-dimensional visualization.1,2 These capabilities are particularly relevant in cardiac surgery, where precise intracardiac manipulation and complex reconstructive techniques are required. Despite this, the adoption of robotic technology in cardiac surgery has historically been slower than in other specialties. This reflects not only the technical demands of cardiac procedures but also the necessity for reproducible, high-quality outcomes.3,4 Over the past 2 decades, robotic cardiac surgery has progressed from experimental feasibility to a clinically validated approach. Improvements in technology, refinement of surgical techniques, and accumulation of outcome data have driven this transition. 5 As a result, robotic cardiac surgery is now positioned at a critical inflection point, with increasing adoption and expanding indications. This review will elaborate on the current available platforms and clinical trials. History of Robotic Surgery The development of robotic surgery can be traced to early telemanipulation systems designed for industrial and military applications, where precise remote control of instruments was required in hazardous environments. 6 These systems provided the conceptual foundation for translating human motion into controlled mechanical action. Initial applications in surgery were limited and focused on enhancing visualization. The AESOP system introduced robotic control of the endoscopic camera, improving stability and reducing reliance on assistants. 7 The ZEUS robotic system represented a significant advancement by enabling surgeons to perform complex procedures using robotic assistance. It played an important role in early robotic cardiac surgery and was used in the landmark Lindbergh telesurgery, which demonstrated the feasibility of transcontinental robotic intervention.8,9 The introduction of the da Vinci Surgical System (Intuitive Surgical, Sunnyvale, CA, USA) in 2000 marked a transformative milestone. By integrating 3-dimensional visualization, articulated instruments, and intuitive control, the da Vinci system enabled surgeons to perform complex procedures with precision. 10 Evolution of Cardiac Surgery Cardiac surgery has evolved through a series of technological and conceptual advances aimed at improving outcomes while reducing invasiveness. Since the introduction of cardiopulmonary bypass enabling surgeons to perform complex intracardiac procedures, the field has been on the cutting edge of surgical innovation. 11 Subsequent efforts focused on minimally invasive approaches including partial sternotomy and minithoracotomy, reducing invasiveness while maintaining operative effectiveness. 12 Robotic technology represented the next step in this evolution, enabling surgeons to perform complex intracardiac totally endoscopic procedures through small ports. 13 This robotic approach has allowed for the expansion of minimally invasive cardiac surgical techniques to procedures that were previously considered too complex, such as aortic valve replacement (AVR) or heart transplantation. Pioneers of Robotic Cardiac Surgery Any discussion of robotic cardiac surgery must not forget its early adopters that lead the way. The advancement of robotic cardiac surgery has been driven by pioneering surgeons who recognized the transformative potential of robotic technology. Chitwood and colleagues played a central role in establishing robotic mitral valve repair as a reproducible and effective procedure, demonstrating outcomes comparable to conventional surgery. 14 Carpentier, Mohr, and Boyd contributed significantly to early robotic coronary and intracardiac procedures, demonstrating feasibility and laying the foundation for modern robotic cardiac surgery. 15 Murphy and Trento helped expand robotic mitral surgery with their dedication to training the future robotic surgeons. These pioneers not only advanced surgical techniques but also developed training frameworks and institutional models that remain essential for successful robotic program implementation. Robotic Surgical Platforms The modern era of robot-assisted surgery is characterized by a rapidly expanding and increasingly competitive landscape of surgical platforms each with distinct technological architectures, regulatory pathways, and clinical validation strategies. Although the da Vinci system established the foundational paradigm for robotic surgery, the entry of multiple competing platforms has introduced new design philosophies aimed at addressing limitations related to cost, scalability, workflow integration, and accessibility. Importantly, the translation of these platforms into cardiac surgery remains variable, with only a limited number demonstrating meaningful clinical application. The da Vinci Surgical System remains the dominant platform in robotic surgery and the only system with a deep, reproducible, multi-institutional experience in robotic cardiac surgery (Table 1). 16 Its leader–follower architecture, immersive surgeon console, EndoWrist instruments, and successive hardware generations from Standard and S through Si, Xi, SP, and the newer da Vinci 5 ecosystem have created a robust platform for cardiothoracic use. Regulatory clearance initially covered general laparoscopic and thoracoscopic applications rather than cardiac procedures specifically, but this proved sufficient for widespread adoption in mitral repair, coronary surgery, and intracardiac cases. Its strength lies in the breadth of clinical validation: robotic mitral repair series, comparative studies versus sternotomy or minithoracotomy, and mature institutional outcomes all derive overwhelmingly from da Vinci–based programs. 17 For cardiac surgery, it is not merely the market leader but effectively the reference standard. As of this publication, the da Vinci 5 system has received cardiac surgical clearance, receiving CE mark approval in July 2025 and Food and Drug Administration 510(k) clearance in 2026. The da Vinci 5 adds haptic force feedback, offers a new surgeon console with improved ergonomics, and provides increased surgeon control of robot functions. It also captures surgeon motions to create a digital record of the operation, allowing data analytics. Table 1.Studies of the da Vinci Surgical System (Intuitive Surgical, Sunnyvale, CA, USA).Study authorYearProcedureDesign N Key findingsBoyd et al. 15 2000TECABFeasibility~45First robotic CABG feasibilityMohr et al. 12 1999Robotic CABGFeasibility100+Established robotic coronary techniquesChitwood et al. 14 2008Mitral repairProspective300Mortality <1%, durable repairMurphy et al. 4 2006Mitral repairCohort127Safe, reproducibleMihaljevic et al. 5 2011Mitral comparisonComparative759Reduced LOS, similar outcomesCao et al. 6 2013MitralMeta-analysis14 studiesImproved perioperative outcomesBonatti et al. 28 2006TECABCohort100+Feasible but complexHalkos et al. 29 2014Hybrid CABGCohort200+Reduced LOS, hybrid benefitUne et al. 27 2014MitralComparative500+Faster recovery roboticWei et al. 41 2024Robotic AVRMulticenter registry2120.9% mortality, no conversions, excellent hemodynamicsAbbreviations: AVR, aortic valve replacement; CABG, coronary artery bypass grafting; LOS, length of stay; TECAB, totally endoscopic coronary artery bypass. Studies of the da Vinci Surgical System (Intuitive Surgical, Sunnyvale, CA, USA). Abbreviations: AVR, aortic valve replacement; CABG, coronary artery bypass grafting; LOS, length of stay; TECAB, totally endoscopic coronary artery bypass. The Versius system (CMR Surgical, Cambridge, UK) is one of the most important non-Intuitive platforms to reach broad international clinical use. Its hallmark is modularity: separate bedside units allow flexible port geometry and potentially a smaller operational footprint relative to traditional integrated carts. Early clinical studies have focused on general, colorectal, gynecologic, and thoracic surgery, and the system has obtained approvals in multiple markets, with continuing regulatory expansion. From a cardiac perspective, Versius remains investigational. Its modular arm architecture is appealing in theory for thoracic access and variable patient anatomy, but published cardiac experience remains limited, and there is no large body of evidence yet supporting robotic mitral or coronary use. 18 The Hugo™ RAS system (Medtronic, Galway, Ireland) similarly uses independent robotic arm carts and an open console strategy. The Medtronic entry into robotics is strategically significant because of the company’s scale and its existing footprint in stapling, energy, visualization, and broader operative technology. Clinical development has been most advanced in urology, with subsequent expansion into general and gynecologic surgery. 19 Hugo is approved in various international markets and has accumulated meaningful clinical volume outside the United States. 19 Cardiac-specific evidence remains sparse, and it is not yet a platform associated with established robotic cardiac surgery programs; however, the system’s modularity and scalability position it as a possible potential future competitor in robotic cardiac surgery. The Senhance system (Asensus Surgical, Durham, NC, USA) occupies a distinctive niche due to its haptic feedback and reusable instrument model. Reusable instrumentation may confer economic advantages compared with disposable-heavy ecosystems, while force feedback offers a technical feature absent from many other platforms. Clinical use has centered on general, colorectal, and gynecologic surgery. However, Senhance has not established a meaningful clinical role in cardiac surgery. 20 The platform remains important conceptually because it demonstrates that future competition in robotics may depend not only on articulation and vision but also on sensory augmentation and cost structure. DEXTER® (Distalmotion, Lausanne, Switzerland) is designed as a hybrid robotic–laparoscopic system that allows surgeons to alternate between direct laparoscopy and robotic control and has 2 patient carts. This may lower barriers for the transition from advanced minimally invasive surgery to robotics. Its current clinical use is centered outside cardiac surgery, and no major cardiac experience has yet emerged. The Ottava™ system (Johnson & Johnson MedTech/Ethicon, Raritan, NJ, USA) remains precommercial but highly relevant because of its operating-table-integrated concept. By embedding robotic arms into the table environment, Ottava aims to reduce device footprint and potentially improve workflow integration. Its eventual impact on cardiac surgery is unknown, but the design philosophy underscores a key trend: future competition may revolve as much around workflow, digital integration, and room efficiency as around pure dexterity. The SSi Mantra system (SS Innovations, Gurgaon, India) is among the most important emerging platforms in the global democratization of robotic surgery. Its significance is not limited to lower acquisition cost; it reflects a broader strategy to create a scalable, accessible, multispecialty robotic ecosystem relevant to low-income and middle-income countries and to regions where cost has historically limited robotic adoption. The system has been used across numerous specialties and has drawn particular attention for its telerobotic demonstrations. For cardiac surgery, the SSi Mantra has been intentionally positioned toward broader applicability, with reported development of instrumentation relevant to pediatric and cardiac practice. The platform’s most important contemporary distinction is its visible commitment to real-world telerobotic use, including long-distance operations that suggest a future role in distributed expertise models. Although the cardiac evidence base is still emerging, the SSi Mantra is one of the few non-Intuitive systems that is being discussed seriously in relation to both cardiac expansion and telerobotic workflows. 21 Regional systems such as Revo-i in South Korea (Meere Company, Hwaseong, South Korea), hinotori™ in Japan (Medicaroid Corporation, Kobe, Japan), and Toumai and MicroHand in China (MicroPort MedBot, Shanghai, China) reflect a broad geographic shift in robotic innovation. The Revo-i and the hinotori systems represent regional innovations in robotic surgery, with regulatory approval in South Korea and Japan, respectively. Both platforms have demonstrated safety in urologic procedures but have not been translated into cardiac surgery. The MicroHand S and Toumai systems represent China’s expanding role in robotic surgery. Clinical trials have demonstrated feasibility in general surgical procedures, and the Toumai system has shown advanced telesurgical capabilities. However, neither system has been applied to cardiac surgery. None of these systems has a mature cardiac evidence base yet, but collectively, they demonstrate that robotic surgery is no longer a single-platform, single-region field. The Revo-i Robotic Surgical System represents one of the first commercially available robotic systems developed outside of the United States and Europe. The system is structurally similar to the da Vinci platform, featuring a closed console and multiple arm configuration. It has received regulatory approval in South Korea and has been used in urologic procedures, including prostatectomy. Although its global footprint remains limited, Revo-i demonstrates the growing international interest in developing independent robotic platforms. The hinotori Surgical Robot System reflects Japan’s entry into the robotic surgery market, combining expertise from Kawasaki Heavy Industries and Sysmex Corporation. 22 The system features a compact design with 8-axis robotic arms and an emphasis on precision and maneuverability. The hinotori system has been approved for clinical use in Japan and is being applied primarily in urologic surgery. Its development highlights the increasing regional diversification of robotic platforms and the strategic importance of domestic innovation. The MicroHand S Robotic System represents a domestically developed robotic platform aimed at expanding access within China. The system features a leader–follower configuration with reusable instruments and a focus on cost reduction. It has been approved for use in urologic and general surgical procedures and reflects China’s broader strategy of developing indigenous medical technologies to reduce reliance on imported systems. The Toumai Surgical Robot is another emerging platform with advanced capabilities, including multiquadrant access and telesurgery integration. The system has been used in long-distance robotic procedures within China, demonstrating its potential in telerobotic applications. Toumai represents a significant step toward integrating robotics with advanced communication technologies. Toumai has been compared to the da Vinci robot in a series of 19 robot-assisted lobectomies, with similar operative time and other perioperative variables. 23 As of March 2026, Toumai has also begun to be used in robot-assisted mitral valve replacement as well as tricuspid repair. The SPORT Surgical System (Titan Medical, Toronto, ON, Canada) is a single-port robotic platform designed to minimize invasiveness by enabling multiple instruments to be deployed through a single incision. Although still in development, the system reflects a broader trend toward reducing the surgical footprint and improving cosmetic outcomes. Its potential applications include urologic and general surgical procedures, with possible future expansion into thoracic and cardiac surgery. Collectively, these platforms illustrate the rapid evolution of robotic surgery from a single dominant system to a diverse and competitive market. Differences in design philosophy including modular versus integrated systems, open versus closed consoles, and reusable versus disposable instrumentation reflect varying strategies aimed at improving accessibility, reducing cost, and enhancing surgical performance. As competition intensifies, continued innovation is expected to drive improvements in functionality, affordability, and global dissemination, ultimately shaping the future of robotic cardiac surgery. Robotic Cardiac Surgery Outcomes Robotic mitral valve repair is the most mature application of robotic cardiac surgery, with a substantial body of evidence demonstrating excellent outcomes. Operative mortality rates are consistently reported below 1% in high-volume centers, with durable repair outcomes comparable to conventional approaches.24,25 A review from 2011 to 2014 of robotic mitral repairs in The Society of Thoracic Surgeons Database showed a reduction in atrial fibrillation and blood transfusion and a shorter hospital stay with no increase in 3-year mitral reintervention rates. 26 In addition to excellent clinical outcomes, robotic mitral valve repair is associated with significant perioperative benefits. These include reduced length of hospital stay, decreased need for blood transfusion, and faster return to normal activities compared with sternotomy. 27 The durability of robotic mitral valve repair is a critical consideration. Long-term studies have demonstrated sustained repair integrity with low rates of reoperation, supporting the use of robotic techniques in appropriate patients. Robotic coronary surgery, including totally endoscopic coronary artery bypass (TECAB), represents a more technically demanding application. Although feasibility has been demonstrated, widespread adoption has been limited by technical complexity and the steep learning curve. 28 Hybrid coronary revascularization has emerged as a promising approach, combining the durability of surgical grafting with the flexibility of percutaneous interventions. 29 Mitral valve surgery represents the most common robotic cardiac procedure. Recent data from The Society of Thoracic Surgeons database showed a 30% increase in robotic mitral valve repair from 2015 to 2021, with 15% of all mitral repair being performed robotically in 2025. 30 Robotic mitral valve repair demonstrates comparable mortality but lower morbidity risks than sternotomy and thoracotomy approaches, with lower conversion rates to valve replacement, shorter intensive care unit stays, and reduced 30-day readmissions. 30 The technique has been successfully applied to various pathologies including rheumatic disease, endocarditis, and ischemic cardiomyopathy. 30 Large institutional series have consistently demonstrated excellent outcomes, including operative mortality rates below 1% and high rates of successful valve repair.31,32 Robotic coronary artery bypass grafting (CABG) remains relatively uncommon, accounting for less than 1% of all CABG procedures. Society of Thoracic Surgeons data from 2006 to 2012 showed robotic CABG use increased modestly from 0.59% to 0.97% of total CABG volume. 33 Robotic minimally invasive direct CABG (MIDCAB) is most commonly used for isolated left anterior descending artery revascularization or combined with percutaneous intervention for multivessel disease. 34 Recent case reports demonstrate the feasibility of combining robotic mitral valve repair with on-pump CABG to the left anterior descending artery (LAD) using robotically harvested internal mammary artery (IMA).35,36 Robotic coronary surgery has been more difficult to standardize and disseminate. Early TECAB trials demonstrated feasibility but highlighted significant technical challenges, including prolonged operative times and steep learning curves.37,38 More recent studies have focused on robot-assisted MIDCAB and hybrid coronary revascularization. Hybrid approaches combining robotic left IMA–LAD grafting with percutaneous coronary intervention have shown promising results, including reduced hospital stay and faster recovery. 39 Despite these advances, randomized trials remain limited, and most evidence is derived from observational studies and institutional series. Robotic AVR (RAVR) remains an emerging and less widely adopted application of robotic cardiac surgery. Unlike mitral valve repair, which is anatomically favorable for robotic access, the aortic valve presents unique challenges due to its position. Early reports have demonstrated the feasibility of robot-assisted AVR using right anterior thoracotomy approaches with robotic assistance for exposure and suturing. 40 These studies suggest that robotic techniques can be used to facilitate minimally invasive AVR while maintaining surgical precision. However, its adoption was limited and reported only as case reports. Recent multicenter data, including the international experience reported by Wei and colleagues, provide the most comprehensive evaluation of RAVR to date. 41 This study included more than 200 patients across multiple high-volume centers and demonstrated that RAVR can be performed safely with excellent early outcomes. Clinical outcomes were particularly notable, with an operative mortality rate of 0.7%, a low stroke rate of 1%, and a renal failure rate of 1.7%. Although these results are highly encouraging, it is important to recognize that RAVR remains in the early phases of adoption. The current evidence is limited to observational data, and further data are needed. Global Adoption and Geographic Variation The global adoption of robotic cardiac surgery reflects broader patterns in health care infrastructure, economic capacity, and technological diffusion (Table 2, Table 3, Table 4). The United States remains the largest market for robotic surgery, driven by early adoption, favorable reimbursement structures, and strong institutional investment. 42 High-volume centers in North America have established robotic cardiac surgery as a viable and reproducible approach, particularly in mitral valve repair. Table 2.Growth in Robotic Surgical Volume.YearTotal global robotic cases (all specialties)2010~200,0002015~500,0002020~900,0002025>1.2 million Growth in Robotic Surgical Volume. Table 3.Cardiac-Specific Robotic Growth.YearTotal global robotic cases (cardiac-specific)Early 2000s<1,000/year2025~30,000–50,000/year Cardiac-Specific Robotic Growth. Table 4.Estimated Growth of Robotic Cardiac Surgery Programs.YearPrograms worldwide2000~52005~202010~502015~1202020~2502025~400+ Estimated Growth of Robotic Cardiac Surgery Programs. Europe has also played a critical role in the development of robotic cardiac surgery, with several pioneering programs contributing to early innovations in coronary revascularization and intracardiac procedures. 43 The adoption pattern in Europe has been heterogeneous, reflecting differences in national health care systems and capital investment strategies. Asia represents one of the fastest-growing regions for robotic surgery, fueled by technological innovation, increasing health care investment, and rising patient demand for minimally invasive procedures. 44 Countries such as India, China, Japan, and South Korea have demonstrated significant growth in robotic surgical programs, with local development of robotic platforms further accelerating adoption. In particular, India has emerged as a key player in the global robotics landscape through the development of cost-conscious platforms such as the SSi Mantra system. These systems aim to reduce the financial barriers associated with robotic surgery, thereby expanding access in emerging markets. 45 The implementation of robotic cardiac surgery programs requires a comprehensive institutional strategy that encompasses training, infrastructure, and patient selection. The adoption curve typically follows a phased approach, beginning with early feasibility cases and progressing to more complex procedures as experience increases.46–48 Institutional commitment is also essential. Successful programs require coordination across multiple disciplines, including surgery, anesthesiology, perfusion, and nursing. The establishment of standardized protocols and dedicated teams contributes to improved efficiency and consistency. Economics of Robotic Cardiac Surgery The economic impact of robotic cardiac surgery remains a complex and multifaceted issue. The initial capital investment required for robotic systems is substantial, often exceeding several million dollars, with ongoing costs related to maintenance, instrumentation, and training. 49 However, a comprehensive economic evaluation must consider both direct and indirect costs. Robotic approaches have been associated with reduced length of hospital stay, decreased intensive care utilization, and lower rates of complications, all of which contribute to potential cost savings. 50 In addition to clinical benefits, robotic surgery may provide strategic advantages for health care institutions. The availability of robotic surgery can enhance institutional reputation, attract patients seeking minimally invasive options, and increase procedural volume in competitive markets. 51 The cost-effectiveness of robotic cardiac surgery is highly dependent on procedural volume. High-volume centers are more likely to achieve favorable economic outcomes due to economies of scale and improved operational efficiency. Conversely, low-volume centers may face challenges in justifying the investment. The emergence of lower-cost robotic platforms has the potential to significantly alter the economic landscape. By reducing acquisition and operational costs, these systems may enable broader adoption and improve access to robotic cardiac surgery, particularly in resource-limited settings. 52 Telerobotic Surgery and Remote Operative Capability Telerobotic surgery represents one of the most transformative potential applications of robotic technology, enabling the performance of surgical procedures across geographic distances. The concept was first demonstrated in the early 2000s with the Lindbergh operation, which established the feasibility of transcontinental robotic surgery. 53 Advances in communication technology, including high-speed data transmission and reduced latency, have renewed interest in telerobotic surgery. Modern robotic systems are increasingly capable of supporting remote operation with improved responsiveness and reliability. The SSi Mantra system has demonstrated successful long-distance telesurgical procedures, highlighting its potential role in expanding access to specialized surgical care. These developments are particularly relevant in cardiac surgery, where expertise is often concentrated in high-volume centers. The ability to deliver advanced surgical care remotely has the potential to reduce disparities in access to complex procedures, particularly in underserved regions. However, significant challenges remain, including the need for robust infrastructure, regulatory frameworks, and cybersecurity safeguards. Teleproctoring and Distributed Surgical Expertise Teleproctoring represents a more immediately practical application of robotic technology, enabling experienced surgeons to provide real-time guidance during procedures. This approach facilitates the dissemination of expertise and accelerates the adoption of robotic techniques. 54 In the context of robotic cardiac surgery, teleproctoring is particularly valuable during the early phases of program development. By providing real-time feedback and guidance, teleproctoring can reduce the learning curve and improve patient safety. Teleproctoring also plays an important role in global surgical education, enabling the transfer of knowledge across geographic boundaries. As robotic surgery continues to expand, teleproctoring is likely to become an integral component of training and credentialing. An initial report of 15 cases including general, urologic, gynecologic, and thoracic operations studied remote surgical consultation to local surgeons using robotic technology. Connectivity was uninterrupted with clear delivery of audio and visual components with no perceived latency. 55 A systematic review of 11 studies of teleproctoring in robotic surgery from 9 countries showed that wired internet had lower latency than wireless internet and that there were no differences between teleproctored and on-site proctoring in terms of operative time, narcotic use, hospital stay, or recovery. 56 Future Directions: Artificial Intelligence, Autonomy, and Digital Surgery The future of robotic surgery will be defined by the integration of artificial intelligence (AI), automation, and digital technologies. These innovations have the potential to enhance surgical precision, improve decision-making, and increase procedural efficiency. AI applications in surgery include computer vision systems capable of recognizing anatomical structures and guiding surgical actions. These systems may provide real-time feedback to surgeons, improving accuracy and reducing the risk of complications. Automation represents another important frontier. Although fully autonomous surgery remains a long-term goal, partial automation of specific tasks has already been demonstrated in experimental settings. These developments suggest that future robotic systems may incorporate varying degrees of autonomy to assist surgeons. Challenges and Limitations Despite the significant advances in robotic cardiac surgery, several challenges remain. High costs continue to limit adoption, particularly in low-income and middle-income countries. The learning curve associated with robotic procedures requires substantial investment in training and institutional support. In addition, disparities in access to robotic technology persist globally, highlighting the need for strategies to expand availability and reduce inequities. Regulatory considerations and standardization of training also represent important challenges as the field continues to evolve. Conclusions Robotic cardiac surgery is entering a transformative phase characterized by technological innovation, expanding clinical evidence, and increasing global adoption. The convergence of robotics and AI has the potential to redefine surgical practice, enabling new levels of precision, efficiency, and accessibility. As barriers to adoption decrease and expertise becomes more widely distributed, robotic cardiac surgery may transition from a specialized capability to a standard component of cardiovascular care worldwide. The future of cardiac surgery will be shaped not only by technological advancements but also by the ability to integrate these innovations into clinical practice in a way that improves patient outcomes and expands access to high-quality care. Footnotes The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Danny Ramzy is a speaker and proctor for Intuitive Surgical. Funding: The authors received no financial support for the research, authorship, and/or publication of this article. ORCID iD: Danny Ramzy https://orcid.org/0000-0002-1445-6610 References